Moreover, notably in the neutrophil‐depleted mouse model, sorafenib treatment resulted in sustained hepatoma regression and did not exacerbate the metastatic potential of hepatoma (Figure 4G,H; Figure S4F, Supporting Information), and this effect was comparable to that observed in TRIB3 knockout mice. Here, TRIB3 is linked to hepatocellular carcinoma.